Biotech Stocks Newsletter – May 3, 2018

0
1106

The Real Question?

This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders. Now it looks like other outlets have started to look to GTBP for new market potential. The real question: Why Haven’t You Looked Into This Company Yet While Countless Industry Vets Are Coming On Board, Now?

SEE FOR YOURSELF CLICK HERE!


Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results

Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Alder management will host a conference call and live audiowebcast with accompanying slides to discuss the results and provide a general business update at 5:00 p.m. ET the same day.

SEE FOR YOURSELF CLICK HERE!


Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares.

Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by a GT Biopharma Inc. for a period beginning May 1, 2018 and ending May. 31, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here

LEAVE A REPLY

Please enter your comment!
Please enter your name here